The discovery of PLK4 inhibitors: (E)-3-((1H-indazol-6-yl)methylene) indolin-2-ones as novel antiproliferative agents

Journal of Medicinal Chemistry

Volumn 56, Issue 15, 2013, Pages 6069-6087

  Laufer, Radoslaw ^a   Forrest, Bryan ^a   Li, Sze Wan ^a   Liu, Yong ^a   Sampson, Peter ^a   Edwards, Louise ^a   Lang, Yunhui ^a   Awrey, Donald E ^a   Mao, Guodong ^a   Plotnikova, Olga ^a   Leung, Genie ^a   Hodgson, Richard ^a   Beletskaya, Irina ^a   Mason, Jacqueline M ^a   Luo, Xunyi ^a   Wei, Xin ^a   Yao, Yi ^a   Feher, Miklos ^a   Ban, Fuqiang ^a   Kiarash, Reza ^a   Green, Erin ^a   Mak, Tak W ^a   Pan, Guohua ^a   Pauls, Henry W ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 STYRYL 1H INDAZOL 6 YL)METHYLEN]INDOLIN 2 ONE; 3 [[3 [2 (PYRIDIN 2 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 3 [[3 [2 (PYRIDIN 3 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 3 [[3 [2 (PYRIDIN 4 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 3 [[3 [2 [6 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 3 YL]VINYL] 1H INDAZOL 6 YL]METHYLEN] INDOLINE 2 ONE; 3 [[3 [4 [(DIMETHYLAMINO)METHYL]STYRYL] 1H INDAZOL 6 YL]METHYLEN) 5 METHOXYINDOLIN 2 ONE 2,2,2 TRIFLUOROACETIC ACID; 3 [[3 [4 [(DIMETHYLAMINO)METHYL]STYRYL] 1H INDAZOL 6 YL]METHYLEN] INDOLIN 2 ONE 2,2,2 TRIFLUOROACETIC ACID; 4 [2 [6 [(2 OXOINDOLIN 3 YLIDENE)METHYL] 1H INDAZOL 3 YL]VINYL]BENZOIC ACID; 5 CHLORO 3 [[3 [2 (PYRIDIN 4 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 ETHYL 3 [[3 [2 (PYRIDIN 3 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 HYDROXY 3 [[3 [2 (PYRIDIN 4 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 METHOXY 3 [[3 [2 (PYRIDIN 3 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 METHOXY 3 [[3 [2 (PYRIDIN 4 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 METHOXY 3 [[3 [2 [6 (4 METHYLPIPERAZIN 1 YL)PYRIDIN 3YL]VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; 5 METHYL 3 [[3 [2 (PYRIDIN 4 YL)VINYL] 1H INDAZOL 6 YL]METHYLEN]INDOLIN 2 ONE; ANTINEOPLASTIC AGENT; AXITINIB; CFI 400437; POLO LIKE KINASE; POLO LIKE KINASE 1; POLO LIKE KINASE 4; POLO LIKE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; INDAZOLES; INDOLES; MICE; MICE, SCID; MODELS, MOLECULAR; PROTEIN-SERINE-THREONINE KINASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84881425734     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400380m     Document Type: Article

References (56)

1. Jackson, J. R.; Patrick, D. R.; Dar, M. M.; Pearl S. Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nature Rev. Cancer 2007, 7, 107-117
2. Jiang, C.; You, Q.; Li, Z.; Guo, Q. Kinesin spindle protein inhibitors as anticancer agents Expert Opin. Ther. Pat. 2006, 16, 1517-1532
3. Schmidt, M.; Bastians, H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs Drug Res. Updates 2007, 10, 162-181
4. Vermeulen, K.; Van Bockstaele, D. R.; Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer Cell Proliferation 2003, 36, 131-149
5. Green, M. R.; Woolery, J. E.; Mahadevan, D. Update on aurora kinase targeted therapeutics in oncology Exp. Opin. Drug Discovery 2011, 6, 291-307
6. Degenhardt, Y.; Lampkin, T. Targeting polo-like kinase in cancer therapy Clin. Cancer Res. 2010, 16, 384-389
7. Coley, H. M. Targeting the cell cycle as a strategy for treating cancer. In Kenichi Trends in Cell Cycle Research; Yoshida, K., Ed.; Research Signpost: Kerala, India, 2008, pp 237-259.
8. Dotan, E.; Cohen, R. B. The ongoing roll-out of aurora kinase inhibitors in cancer treatment Drugs Future 2010, 35, 845-858
9. Archambault, V.; Glover, D. M. Polo-like kinases: conservation and divergence in their functions and regulation Nature Rev., Mol. Cell Biol. 2009, 10, 265-275
10. Barr, F. A.; Silljé, H. H. W.; Nigg, E. A. Polo-like kinases and the orchestration of cell division Nature Rev. Mod. Cell 2004, 5, 429-440
11. Schoffski, P. Polo-like kinase inhibitors in preclinical and early clinical development Oncologist 2009, 14, 559-570
12. Sillibourne, J. E.; Bornens, M. Polo-like kinase 4: the odd one out of the family Cell Div. 2010, 5, 25-34
13. Bettencourt-Dias, M.; Rodrigues-Martins, A.; Carpenter, L.; Riparbelli, M.; Lehmann, L.; Gatt, M. K.; Carmo, N.; Balloux, F.; Callaini, G.; Glover, D. M. SAK/PLK4 is required for centriole duplication and flagella development Curr. Biol. 2005, 15, 2199-2207
14. Habedanck, R.; Stierhof, Y.-D.; Wilkinson, C. J.; Nigg, E. A. The Polo kinase PLK4 functions in centriole duplication Nature Cell Biol. 2005, 7, 1140-1146
15. Kleylein-Sohn, J.; Westendorf, J.; Le Clech, M.; Habedanck, R.; Stierhof, Y.-D.; Nigg, E. A. PLK4-induced centriole biogenesis in human cells Dev. Cell 2007, 13, 190-202
16. Peel, N.; Stevens, N. R.; Basto, R.; Raff, J. W. Overexpressing centriole-replication proteins in vivo induces centriole overduplication and de novo formation Curr. Biol. 2007, 17, 834-843
17. Hudson, J. W.; Kozarova, A.; Cheung, P.; Macmillan, J. C.; Swallow, C. J.; Cross, J. C.; Dennis, J. W. Late mitotic failure in mice lacking Sak, a polo-like kinase Curr. Biol. 2001, 11, 441-446
18. Cunha-Ferreira, I.; Rodrigues-Martins, A.; Bento, I.; Riparbelli, M.; Zhang, W.; Laue, E.; Callaini, G.; Glover, D. M.; Bettencourt-Dias, M. The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4 Curr. Biol. 2009, 19, 43-49
19. Rogers, G. C.; Rusan, N. M.; Roberts, D. M.; Peifer, M.; Rogers, S. L. The SCF/Slimb ubiquitin ligase regulates PLK4/Sak levels to block centriole reduplication J. Cell Biol. 2009, 184, 225-238
20. Guderian, G.; Westendorf, J.; Uldschmid, A.; Nigg, E. A. PLK4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation J. Cell Sci. 2010, 123, 2163-2169
21. Holland, A. J.; Lan, W.; Niessen, S.; Hoover, H.; Cleveland, D. W. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability J. Cell Biol. 2010, 188, 191-198
22. Brownlee, C. W.; Klebba, J. E.; Buster, D. W.; Rogers, G. C. The protein phosphatase 2A regulatory subunit Twins stabilizes PLK4 to induce centriole amplification J. Cell Biol. 2011, 195, 231-243
23. Ganem, N. J.; Godinho, S. A.; Pellman, D. A mechanism linking extra centrosomes to chromosomal instability Nature 2009, 460, 278-282
24. Mason, J.; Wei, S.; Luo, S.; Nadeem, V.; Kiarash, R.; Huang, P.; Awrey, A.; Leung, G.; Beletskaya, I.; Feher, M.; Forrest, B.; Laufer, R.; Sampson, P.; Li, S.-W.; Liu, Y.; Lang, Y.; Pauls, H. W.; Mak, T. W.; Pan, J. G. Inhibition of Polo-like kinase 4 as an anti-cancer strategy. In Book of Abstracts, AACR 102nd Annual Meeting, Orlando, FL, April 2-6, 2011, LB-215.
25. Mak, T. W. Targeting the Cell Cycle in Cancer: TTK (MPS1) and PLK4 as Novel Mitotic Targets. In Book of Abstracts, AACR 103rd Annual Meeting, Chicago, IL, April 1-5, 2012.
26. Hu, Z.; Fan, C.; Oh, D. S.; Marron, J. S.; He, X.; Qaqish, B. F.; Livasy, C.; Carey, L. A.; Reynolds, E.; Dressler, L.; Nobel, A.; Parker, J.; Ewend, M. G.; Sawyer, L. R.; Wu, J.; Liu, Y.; Nanda, R.; Tretiakova, M.; Orrico, A. R.; Dreher, D.; Palazzo, J. P.; Perreard, L.; Nelson, E.; Mone, M.; Hansen, H.; Mullins, M.; Quackenbush, J. F.; Ellis, M. J.; Olopade, O. I.; Bernard, P. S.; Perou, C. M. The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 2006, 7, 96-108
27. van di Vijver, M. J.; He, Y. D.; van 't Veer, L.; Dai, H.; Hart, A. A. M.; Voskuil, D. W.; Schreiber, G. J.; Peterse, J. L.; Roberts, C.; Marton, M. J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E. T.; Friend, S. H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer N. Engl. J. Med. 2002, 347, 1999-2009
28. Miller, L. D.; Smeds, J.; George, J.; Vega, V. B.; Vergara, L.; Ploner, A.; Pawitan, Y.; Hall, P.; Klaar, S.; Liu, E. T.; Bergh, J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 13550-13555
29. Johnson, E. F.; Stewart, K. D.; Woods, K. W.; Giranda, V. L.; Luo, Y. Pharmacological and Functional Comparison of the Polo-Like Kinase Family: Insight into Inhibitor and Substrate Specificity Biochemistry 2007, 46, 9551-9563
30. Tovar, C.; Higgins, B.; Deo, D.; Kolinsky, K.; Liu, J.-J.; Heimbrook, D. C.; Vassilev, L. T. Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: implications for therapy Cell Cycle 2010, 9, 3364-3375
31. Diels, G. S. M.; Ten Holte, P.; Freyne, E. J. E.; Grand-Perret, T. A. R.; Van Emelen, K.; Embrechts, W. C. J.; Bonnet, P. G. A. Pyrrolopyrimidines. PCT Int. Appl. WO 2009016132, 2009.
32. Buijnsters, P. J. J. A.; Verdonck, M. G. C.; Van Emelen, K.; Bonnet, P. G. A. 4-Aryl-2-anilino-pyrimidines as PLK kinase inhibitors. PCT Int. Appl. WO 2009112439, 2009.
33. Pauls, H. W. PLK4 Inhibitors of Novel Structure as Potent Anti-proliferative Agents. Book of Abstracts, 241st ACS National Meeting, Anaheim, CA, March 27-31, 2011, MEDI 189.
34. Baber, C.; Shirley, W.; Gao, Y.; Feher, M. The Use of Consensus Scanning in Ligand-Based Virtual Screening J. Chem. Inf. Model. 2006, 46, 277-288
35. Feher, V. A.; Lawson, D. J. Approaches to kinase homology modeling: successes and consideration for the structural kinome. In Kinase Inhibitor Drugs; Li, R.; Stafford, J. A., Eds.; John Wiley & Sons Inc.: Hoboken, NJ, 2009; Chapter 17, pp 433-460.
36. GOLD, version 3.2; Cambridge Crystallographic Database: Cambridge, U.K., 2007.
37. Glide, version 2007; Schrodinger Inc.: Portland, OR, 2007.
38. Lackey, K.; Cory, M.; Davis, R.; Frye, S. V.; Harris, P. A.; Hunter, R. N.; Jung, D. K.; O. Bradley McDonald, O. B.; McNutt, R. W.; Peel, M. R.; Rutkowske, R. D.; Veal, J. M.; Wood, E. R. The Discovery of Potent cRaf1 Kinase Inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 223-226
39. Braud, E.; Duflos, M.; Nourrisson, M.-R.; Tonnerre, A.; Picot, C.; Le Baut, G.; Renard, P.; Pfeiffer, B.; Tucker, G. Potential Inhibitors of Angiogenesis, Part I: 3-(Imidazole-4(5)-ylmethylene)indoin-2-ones J. Enzyme Inhib. Med. Chem. 2003, 18, 243-252
40. Krishnamurthy, V. V. Excitation-Sculptured Indirect-Detection Experiment (EXSIDE) for Long-Range CH Coupling-Constant Measurement J. Magn. Reson. 1996, 121, 33-41
41. Li, S.; Tran, H.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases J. Med. Chem. 1998, 41, 2588-2603
42. Höttecke, N.; Liebeck, M.; Baumann, K.; Schubenel, R.; Winkler, E.; Steiner, H.; Schmidt, B. Inhibition of c-secretase by the CK1 inhibitor IC261 does not depend on CK1δ Bioorg. Med. Chem. Lett. 2010, 20, 2958-2963
43. Walsby, E.; Walsh, V.; Pepper, C.; Burnett, A.; Mills, K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts Haematologica 2008, 93, 662-669
44. MOE (Molecular Operating Environment), version 2005.06; Chemical Computing Group Inc.: 1010 Sherbrooke St. West, Suite 910, Montreal, Quebec H3A 2R7, Canada, 2005.
45. Ewing, T.; Baber, J. C.; Feher, M. Novel 2D Fingerprints for Ligand-Based Virtual Screening J. Chem. Inf. Model. 2006, 46, 2423-2431
46. Wombat 2007.01; Sunset Molecular Discovery LLC: Santa Fe, NM, 87505, 2007.
47. Olah, M.; Mracec, M.; Ostopovici, L.; Rad, R.; Bora, A.; Hadaruga, N.; Olah, I.; Banda, M.; Simon, Z.; Mracec, M.; Oprea, T. I. WOMBAT: World of Molecular Bioactivity. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed; Wiley-VCH: New York, 2004; pp 223-239.
48. Fancelli, D.; Berta, D.; Bindi, S.; Cameron, A.; Cappella, P.; Carpinelli, P.; Catana, C.; Forte, B.; Giordano, P.; Giorgini, M. L.; Mantegani, S.; Marsiglio, A.; Meroni, M.; Moll, J.; Pittalà, V.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Varasi, M.; Vulpetti, A.; Vianello, P. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition J. Med. Chem. 2005, 48, 3080-3084
49. Corina, version 3.2; Molecular Networks GmbH: Erlangen, Germany, 2006.
50. Analyse/visualise H bonds for database with DBV Browser, SVL exchange, http://svl.chemcomp.com (accessed April 12, 2012).
51. Dubinina, G. G.; Chupryna, O. O.; Platonov, M. O.; Borisko, P. O.; Ostrovska, G. V.; Tolmachov, A. O.; Shtil, A. A. In silico design of protein kinase inhibitors: successes and failures Anti-Cancer Agents Med. Chem. 2007, 7, 171-188
52. Feher, M.; Ewing, T. Global or local QSAR: Is there a way out? QSAR Comb. Sci. 2009, 28, 850-855
53. ADMET Predictor, v5.0; Simulations Plus: Lancaster, CA, 2012.
54. Su, T.; Naughton, M. A.; Smyth, M. S.; Rose, J. W.; Arfsten, A. E.; McCowan, J. R.; Jakubowski, J. A.; Wyss, V. L.; Ruterbories, K. J.; Sall, D. J.; Scarborough, R. M. J. Med. Chem. 1997, 40, 4308-4318
55. Usansky, J. I.; Desai, A.; Tang-Liu, D. PK Functions for Microsoft Excel; http://www.boomer.org/pkin/soft.html (accessed November, 2008).
56. ACD/Structure Designer, version 12.01; Advanced Chemistry Development, Inc.: Toronto, ON, Canada, 2012.